비소세포암종의 Epidermal Growth Factor Receptor발현과 EGFR 돌연변이와의 관계
Epidermal Growth Factor Receptor Expression of Non-small Cell Carcinoma and Its Relationship with Genomic Mutation
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background : It has recently been clarified that epidermal growth factor receptor (EGFR), which is a receptor tyrosine kinase of the erbB family, is abnormally activated in non-small cell lung carcinomas (NSCLC) and this fact is being utilized for creating targeted therapy. In this study, we aimed to identify the frequency of the EGFR expression and gene mutation in NSCLC, and to determine the correlation between them. Methods : Immunohistochemical staining for EGFR, C-erbB-2, cytokeratin 7, p53 and thyroid transcription factor-1, and EGFR mutation analysis were performed using paraffin-embedded archival tissue from 228 cases of NSCLC; this included 112 squamous cell carcinomas and 116 adenocarcinomas. Results : An EGFR expression and gene mutation occurred in 112 casees (53.5%) and 52 cases (22.8 %), respectively. EGRF mutation was more frequent in the adenocarcinomas than in the squamous cell carcinomas, in non-smokers than in smokers, and in females than in males. EGFR mutation was significantly associated with an EGFR protein expression, and especially in adenocarcinomas. Conclusion : The EGFR expression in NSCLC was associated with EGFR mutation, and especially in adenocarcinomas. More studies are needed to prove the clinical significance of the EGFR expression for creating targeted therapy to treat NSCLC.
Abstract
Background : It has recently been clarified that epidermal growth factor receptor (EGFR), which is a receptor tyrosine kinase of the erbB family, is abnormally activated in non-small cell lung carcinomas (NSCLC) and this fact is being utilized for creating targeted therapy. In this study, we aimed to identify the frequency of the EGFR expression and gene mutation in NSCLC, and to determine the correlation between them. Methods : Immunohistochemical staining for EGFR, C-erbB-2, cytokeratin 7, p53 and thyroid transcription factor-1, and EGFR mutation analysis were performed using paraffin-embedded archival tissue from 228 cases of NSCLC; this included 112 squamous cell carcinomas and 116 adenocarcinomas. Results : An EGFR expression and gene mutation occurred in 112 casees (53.5%) and 52 cases (22.8 %), respectively. EGRF mutation was more frequent in the adenocarcinomas than in the squamous cell carcinomas, in non-smokers than in smokers, and in females than in males. EGFR mutation was significantly associated with an EGFR protein expression, and especially in adenocarcinomas. Conclusion : The EGFR expression in NSCLC was associated with EGFR mutation, and especially in adenocarcinomas. More studies are needed to prove the clinical significance of the EGFR expression for creating targeted therapy to treat NSCLC.
참고문헌 (34)
- Jemal A, "Cancer statistics, 2006", CA Cancer J Clin, 56, pp.106~130 (2006)
- Mountain CF, "The international system for staging lung cancer", Semin Surg Oncol, 18, pp.106~115 (2000)
- Herbst RS, "Targeted therapy in non-small-cell lung cancer", Oncology, 16, pp.19~24 (2002)
- Massarelli E, "Use of novel second-line targeted therapies in non-small cell lung cancer", Semin Oncol, 33(1), pp.9~19 (2006)
- Paez JG, "EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy", Science, 304, pp.1497~1500 (2004)
- Prudkin L, "Epidermal growth factor receptor abnormalities in lung cancer: pathogenetic and clinical implications", Ann Diagn Pathol, 10, pp.306~315 (2006)
- Jacobs TW, "Specificity of HercepTest in determining the HER-2", neu status of breast cancers using the United States Food and Drug Administration-approved scoring system, 1999, pp.17, 1983~1987
- Fernandez Val JF, "Cell proliferation, nuclear ploidy, and EGFR and HER2", neu tyrosine kinase oncoproteins in infiltrating ductal breast carcinoma, 2002, pp.138, 69~72
- Slamon DJ, "Human breast cancer: correlation of relapse and survival with amplification of the HER-2", neu oncogene, 1987, pp.235, 177~182
- Gusterson BA, "Prognostic importance of c-erbB-2 expression in breast cancer", J Clin Oncol, 10, pp.1049~1056 (1992)
- Hirsch FR, "Evaluation of HER- 2", neu gene amplification and protein expression in non-small cell lung carcinomas, 2002, pp.86, 1449~1456
- Han H, "Prognostic value of immunohistochemical expressions of p53, HER-2", neu, and bcl-2 in stage I non-small-cell lung cancer, 2002, pp.33, 105~110
- Gehring WJ, "Homeo boxes in the study of development", Science, 236, pp.124~152 (1987)
- Lazzaro D, "The transcription factor, TTF-1, is expressed at the onset of thyroid and lung morphogenesis and in restricted regions of fetal brain", Development, 113, pp.1093~1104 (1990)
- Bejarano PA, "Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas", Mod Pathol, 9, pp.445~452 (1996)
- Khoor A, "Utility of surfactant protein B precursor and thyroid transcription factor-1 in differentiating adenocarcinoma of the lung from malignant mesothelioma", Hum Pathol, 30, pp.695~700 (1999)
- Kimura S, "The T", ebp null mouse: thyroidspecific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary, 1996, pp.10, 60~69
- Miettinen M, "Variable expression of keratins and nearly uniform lack of thyroid transcription factor I in thyroid anaplastic carcinoma", Hum Pathol, 31, pp.1139~1145 (2000)
- Cohen S, "A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles", J Biol Chem, 257, pp.1523~1531 (1982)
- Normanno N, "Epidermal growth factor receptor (EGFR) signaling in cancer", Gene, 366, pp.2~16 (2006)
- Franklin WA, "Epidermal growth factor receptor family in lung cancer and premalignancy", Semin Oncol, 29, pp.3~14 (2002)
- Suzuki S, "Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: an immunohistochemical and fluorescence in situ hybridization study", Cancer, 103, pp.1265~1273 (2005)
- Nakamura H, "Survival impact of epidermal growth factor receptor overexpression in patients with non-small-cell lung cancer: a meta-analysis", Thorax, 61, pp.140~145 (2006)
- Hirsch FR, "Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis", J Clin Oncol, 21, pp.3798~3807 (2003)
- Ahn Jin Hee, "Epidermal Growth Factor Receptor (EGFR) Expression in Operable Non-small Cell Lung Carcinoma", Journal of Korean Medical Science, 19(4), pp.529~535 (2004), 대한의학회
- Scagliotti GV, "The biology of epidermal growth factor receptor in lung cancer", Clin Cancer Res, 10, pp.4227~4232 (2004)
- Perez-Soler R, "Determinants of tumor response and survival with erlotinib in patients with nonsmall- cell lung cancer", J Clin Oncol, 22, pp.3238~3247 (2004)
- Shigematsu H, "Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers", Int J Cancer, 118, pp.257~262 (2006)
- Shigematsu H, "Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers", J Natl Cancer Inst, 97, pp.339~346 (2005)
- Tsao AS, "Clinicopathological characteristics of the EGFR gene mutation in non-small cell lung cancer", J Thoracic Oncol, 1, pp.231~239 (2006)
- Han SW, "Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib", J Clin Oncol, 23, pp.2493~2501 (2005)
- Hirsch FR, "Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes", J Clin Oncol, 23, pp.6838~6845 (2005)
- Cappuzzo F, "Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer", J Natl Cancer Inst, 97, pp.643~655 (2005)
- 이승구, "비소세포 폐암종의 상피성장인자 수용체 상태와 임상-병리학적 연관성: 단백 발현, 유전자 증폭 및 생존분석", The Korean Journal of Pathology, 41(6), pp.387~392 (2007), 대한병리학회